Agios Pharmaceuticals (NASDAQ:AGIO) Lifted to “Hold” at StockNews.com

StockNews.com upgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO) from a sell rating to a hold rating in a report released on Wednesday morning.

Other analysts have also recently issued reports about the stock. Leerink Partners cut shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $60.00 to $56.00 in a report on Friday, September 27th. Leerink Partnrs lowered Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Royal Bank of Canada restated an “outperform” rating and set a $55.00 target price on shares of Agios Pharmaceuticals in a research note on Thursday, September 19th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Friday, September 20th. Finally, Raymond James reaffirmed an “outperform” rating and issued a $51.00 price objective on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Agios Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $52.00.

Agios Pharmaceuticals Trading Up 3.9 %

AGIO stock opened at $43.70 on Wednesday. The company has a 50-day moving average price of $44.58 and a 200 day moving average price of $40.85. Agios Pharmaceuticals has a 12 month low of $19.80 and a 12 month high of $53.28. The stock has a market cap of $2.48 billion, a PE ratio of -6.91 and a beta of 0.75.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.60) by ($0.09). The business had revenue of $8.60 million during the quarter, compared to the consensus estimate of $9.34 million. Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. The company’s revenue for the quarter was up 28.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.51) EPS. Sell-side analysts forecast that Agios Pharmaceuticals will post -4.87 EPS for the current year.

Insider Buying and Selling

In other Agios Pharmaceuticals news, CEO Brian Goff sold 11,091 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $42.75, for a total transaction of $474,140.25. Following the completion of the sale, the chief executive officer now directly owns 78,792 shares in the company, valued at approximately $3,368,358. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the transaction, the chief financial officer now owns 20,158 shares in the company, valued at approximately $988,346.74. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Brian Goff sold 11,091 shares of the company’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $42.75, for a total value of $474,140.25. Following the completion of the sale, the chief executive officer now owns 78,792 shares in the company, valued at $3,368,358. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.93% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several hedge funds have recently bought and sold shares of AGIO. Creative Planning increased its holdings in shares of Agios Pharmaceuticals by 35.8% during the 3rd quarter. Creative Planning now owns 15,640 shares of the biopharmaceutical company’s stock valued at $695,000 after purchasing an additional 4,120 shares in the last quarter. Inspire Investing LLC increased its holdings in Agios Pharmaceuticals by 13.7% in the third quarter. Inspire Investing LLC now owns 9,228 shares of the biopharmaceutical company’s stock valued at $410,000 after buying an additional 1,113 shares in the last quarter. CWM LLC increased its stake in shares of Agios Pharmaceuticals by 554.7% in the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 1,836 shares in the last quarter. Handelsbanken Fonder AB boosted its position in Agios Pharmaceuticals by 10.5% during the third quarter. Handelsbanken Fonder AB now owns 17,823 shares of the biopharmaceutical company’s stock worth $792,000 after purchasing an additional 1,700 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in Agios Pharmaceuticals during the third quarter valued at $705,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.